Navigation Links
Endu Receives Gold Medal for Outstanding Chinese Patented Invention Award
Date:3/3/2008

NANJING, CHINA, March 4 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, announced today that the company is a gold medal winner of the 10th Outstanding Chinese Patented Invention Award bestowed by the State Intellectual Property Office of the People's Republic of China (SIPO).

The award, established by SIPO in 1989, is the exclusive government patent award held every two years to encourage technology innovation and to boost intellectual property protection, and has been approved by the World Intellectual Property Organization (WIPO).

SIPO received 318 applicants for the 10th Outstanding Chinese Patented Invention Award from all over the country recommended by the ministries, local IP administrations, nation-level enterprises, the Chinese Academy of Sciences and the members of Chinese Academy of Engineering. Fifteen outstanding Chinese patent invention gold medal winners were selected after several rounds of strict examination.

The award is for the methodology pioneered by Simcere to produce Endu, a modified version of endostatin, which has brought tremendous social benefit to thousands of patients across China. Endu has been engineered to contain an additional nine-amino acid sequence to enhance protein purification, solubility and stability and has been shown to improve the function of endostatin, which is a genetically engineered protein that interferes with the growth of blood vessels to a tumor, thereby starving and preventing the growth of tumor cells.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stoke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Highlands Acquisition Corp. Receives Non-Compliance Letter From Amex
2. Vapotherm CEO Receives Top Business Leadership Award From World Trade Center Institute
3. Fujifilm Receives FDA Approval for Unity SpeedSuite(TM)
4. Bart De Strooper receives prestigious $200,000 Alzheimer Prize
5. The Female Health Company Receives USAID DELIVER PROJECT Order for 6.1 Million Units
6. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
7. Boca Pharmacal Receives FDA Approval for Carbinoxamine Oral Solution
8. IDC receives patent on dual energy imaging technology
9. Kryptiq Customer Receives HIMSS Nicholas E. Davies Award of Excellence
10. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
11. Healthy Start of Southwest Florida Receives Grant From March of Dimes to Assess Needs of Pregnant Women and Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
Breaking Medicine Technology: